IGM Biosciences is expected to report its fourth-quarter (Q4) 2024 earnings per share (EPS) of approximately ($0.84), according to the estimates by HC Wainwright. The estimated revenue for the same period is $3.34 million1.
However, there are no available estimates for the first quarter (Q1) 2025 EPS and revenue. It is important to note that the company's performance can be influenced by various factors such as market conditions, company performance, and industry trends. Therefore, the actual earnings and revenue figures may vary from the estimates.